RHEACELL

Executive Summary

RHEACELL is a fully integrated, clinical late-stage biopharmaceutical company headquartered in Heidelberg, Germany, dedicated to developing first-in-class stem cell therapies based on its proprietary ABCB5+ mesenchymal stromal cell (MSC) platform. The company targets severe immune and inflammation-driven diseases with high unmet medical need, with its lead program in Epidermolysis bullosa (EB) advancing in Phase 3 trials. RHEACELL's ABCB5+ MSCs possess unique immunomodulatory and regenerative properties, offering potential disease-modifying treatment for patients lacking satisfactory options. The company's end-to-end capabilities, from cell manufacturing to clinical development, position it to address significant markets. With a strong scientific foundation and a clear regulatory pathway, RHEACELL aims to become a leader in MSC-based therapies for debilitating conditions. Key upcoming milestones include pivotal data readouts from its Phase 3 EB trial, which could support registration filings in Europe and the US, and expansion of its pipeline into additional indications such as graft-versus-host disease and inflammatory bowel disease. The company is backed by experienced management and a robust intellectual property portfolio surrounding ABCB5+ MSCs.

Upcoming Catalysts (preview)

• Q1 2027Phase 3 top-line data readout for Epidermolysis bullosa50% success
• Q3 2027Regulatory submission (EMA or FDA) for ABCB5+ MSCs in EB40% success
• H2 2026Series C or late-stage financing round to support commercial launch70% success